Revenue Recognition - Schedule of net revenue from collaborative arrangements (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue Recognition and Collaboration Arrangements
Total net royalty revenue	$ 67,259	$ 67,257	$ 224,623	$ 265,536
Royalty revenue
Revenue Recognition and Collaboration Arrangements
Total net royalty revenue	53,558	62,150	172,681	260,429
GSK
Revenue Recognition and Collaboration Arrangements
Total net royalty revenue	53,558	62,150	172,681	260,429
GSK | Royalty revenue
Revenue Recognition and Collaboration Arrangements
Royalties	57,014	65,606	183,049	270,797
Less: amortization of capitalized fees paid to a related party	(3,456)	(3,456)	(10,368)	(10,368)
GSK | RELVAR/BREO
Revenue Recognition and Collaboration Arrangements
Royalties	45,585	55,663	150,922	170,753
GSK | ANORO
Revenue Recognition and Collaboration Arrangements
Royalties	11,429	9,943	32,127	28,015
GSK | TRELEGY
Revenue Recognition and Collaboration Arrangements
Royalties	$ 0	$ 0	$ 0	$ 72,029